Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe
6/8/2012 9:59:51 AM
FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) announced today that its investigational compound known as AR-42 has been granted orphan-drug designation by the European Medicines Agency (EMA) for the treatment of meningioma and schwannoma. Meningiomas are benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity for those affected individuals. Schwannomas are benign tumors that can present in different locations within the brain, spinal cord and peripheral nerves, which may cause substantial morbidity for those affected individuals. In May, 2012 the EMA designated AR-42 an orphan drug for the treatment of neurofibromatosis type 2 (NF2), a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts and neurofibromas of the skin.